SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company’s role in the manufacturing of Veklury® (remdesivir), Gilead Sciences’ antiviral drug for the treatment of patients with COVID-19 requiring hospitalization. Veklury is formulated with Ligand’s Captisol® technology. Approved yesterday by the U.S. Food and Drug Administration, Veklury is the first and only approved COVID-19 … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “COVID-19 Medical Devices Companies: Weekly Pacesetters” report has been added to ResearchAndMarkets.com’s offering. This report offers an in-depth focus on recent week’s key COVID-19 business news for Medical Devices companies worldwide. 100+ COVID-19 business news of global Medical Devices companies are summarized every week which include news related to diagnostics/devices advances, therapeutics experiments … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Daily Report: COVID-19 Vaccine Development News – Frankfurt Edition” report has been added to ResearchAndMarkets.com’s offering. This report offers, at Frankfurt 9am, daily updates for 20+ global news related to COVID-19 Vaccine Development, comprehensively tracked, compiled and curated from global as well as regional and local news media. It provides a quick glance … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Companion Diagnostics in the COVID-19 Era: Market Analysis and Opportunities” report has been added to ResearchAndMarkets.com’s offering. This report provides a comprehensive market analysis and business planning tool for the market for tests that are aligned with pharmaceutical treatment. Especially in oncology, companion diagnostics are rising to the forefront of pharmaceutical development and … [Read more…]

LIVERMORE, Calif.–(BUSINESS WIRE)–Performant Financial Corporation (Nasdaq:PFMT), (“the Company”), a provider of technology-enabled recovery and related analytics services, today announced that it has contracted over four million lives for its recently launched Premium Accuracy offering, a Medicare Secondary Payer (MSP) service for Medicare Advantage Plans. Medicare Advantage (MA) is the fastest-growing segment of private Health insurance … [Read more…]

SANTA MONICA, Calif.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled, virtualized outpatient healthcare treatment company, today announced it will report financial results for the third quarter 2020 on Thursday, November 5, 2020 after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / … [Read more…]

Marc Schegerin, MD and Sapna Srivastava, PhD join as new board members and Micah Zajic as Chief Business Officer WATERTOWN, Mass.–(BUSINESS WIRE)–SQZ Biotechnologies (SQZ), a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions, today announced the appointments of Marc Schegerin, MD and Sapna Srivastava, PhD to … [Read more…]

VANGARD trial discontinued due to evolving COVID-19 treatment landscape, recent feedback from FDA regarding regulatory and development path, and interim analysis of trial data Enrollment expected to resume for ongoing Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH) MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–$PHAS—PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused … [Read more…]

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named one of the top 100 adoption-friendly workplaces in the United States by the Dave Thomas Foundation for Adoption, ranking number 39 overall and number two in the pharmaceutical category. The list recognizes organizations with the most robust adoption benefit programs, comparing financial … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designations (ODD) for KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM). Both orphan diseases are autoimmune inflammatory myopathies … [Read more…]